Solventum (SOLV) Q1 Earnings: How Key Metrics Compare to Wall Street Estimates

For the quarter ended March 2025, Solventum (SOLV) reported revenue of $2.07 billion, up 2.7% over the same period last year. EPS came in at $1.34, compared to $2.08 in the year-ago quarter.The reported revenue compares to the Zacks Consensus Estimate of $2 billion, representing a surprise of +3.37%. The company delivered an EPS surprise of +12.61%, with the consensus EPS estimate being $1.19.While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expectations to determine their next move, some key metrics always offer a more accurate picture of a company's financial health.As these metrics influence top- and bottom-line performance, comparing them to the year-ago numbers and what analysts estimated helps investors project a stock's price performance more accurately.Here is how Solventum performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts: Net Sales- MedSurg: $1.16 billion compared to the $1.10 billion average estimate based on three analysts. Net Sales- Purification and Filtration: $242 million versus $242.25 million estimated by three analysts on average. Net Sales- Health Information Systems: $329 million compared to the $319.96 million average estimate based on three analysts. Net Sales- Dental Solutions: $328 million versus the three-analyst average estimate of $325.61 million. Operating Income- MedSurg: $206 million versus $229.10 million estimated by two analysts on average. Operating Income- Purification and Filtration: $35 million versus the two-analyst average estimate of $31.92 million. Operating Income- Health Information Systems: $109 million compared to the $104.45 million average estimate based on two analysts. Operating Income- Dental Solutions: $78 million compared to the $95.98 million average estimate based on two analysts. View all Key Company Metrics for Solventum here>>>Shares of Solventum have returned -4.5% over the past month versus the Zacks S&P 500 composite's +11.3% change. The stock currently has a Zacks Rank #2 (Buy), indicating that it could outperform the broader market in the near term.7 Best Stocks for the Next 30 DaysJust released: Experts distill 7 elite stocks from the current list of 220 Zacks Rank #1 Strong Buys. They deem these tickers "Most Likely for Early Price Pops."Since 1988, the full list has beaten the market more than 2X over with an average gain of +23.9% per year. So be sure to give these hand picked 7 your immediate attention. See them now >>Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Solventum Corporation (SOLV): Free Stock Analysis ReportThis article originally published on Zacks Investment Research (zacks.com).Zacks Investment ResearchWeiter zum vollständigen Artikel bei Zacks Weiter zum vollständigen Artikel bei Zacks